³Ô¹ÏÍø

ChrisÌýcurrentlyÌýservesÌýonÌýseveralÌýcorporateÌýboards,ÌýincludingÌýTragaraÌýPharmaceuticals,ÌýAsterandÌýCorp.,ElcelyxÌýandÌýNimbusÌýPharmaceuticals,ÌýandÌýachievedÌýsuccessfulÌýexitsÌýwithÌýAvidia,ÌýMorphotech,ÌýThreshold,ÌýSciodermÌýand Nimbus.ÌýPreviously, he served as the President and CEO of Ribozyme; Senior Vice President, Research at SmithKline Beecham; Vice President, Discovery Research at Upjohn and President, Colorado State ³Ô¹ÏÍø. He received the "Outstanding Research of Year" Award from the International Society of Quantum Biology, the "W. E. Upjohn Award" for contributions in biotechnology and a Lifetime Achievement Award and Lifetime Achievement AwardÌýfrom the Colorado Biosciences Association. Chris currently serves on several corporate boards, including Catalyst Biosciences, Galleon Pharmaceuticals, GlobeImmune, Stemgent, Tragara Pharmaceuticals and OptiScan and achieved successful exits with Avidia, Morphotek, and Threshold. He earned a B.S. in Chemistry and Mathematics from Cornell ³Ô¹ÏÍø, a Ph.D. in Chemistry from Indiana ³Ô¹ÏÍø and an Honorary J.D. from Cornell College.